RESUMO
Objective To analyze the effect of compound Minwei on serum interleukin-4(IL-4),interferon-γ(IFN-γ)value in children with acute urticaria.Methods in our hospital from March 2015 to October 2016 received 148 cases of children with acute urticaria eczema,were randomly divided into study group and control group,74 cases in each group,study the application of compound chlorphenamine maleate and vitamin syrup for treatment,the control group were applied paeonol ointment treatment,curative effect,evaluation of children with symptoms before and after treatment respectively,and detection serum IL-4 and IFN-levels.Results before treatment,the two groups had no statistical significance with symptom score,serum IL-4,IFN-levels difference(P>0.05);after treatment,the clinical efficacy of the study group,serum IFN-γ levels higher than the control group,the serum level of IL-4 score,symptoms than the control group,the difference has statistical significance(P<0.05).Conclusion acute eczema urticaria children with compound Minwei syrup treatment,can significantly relieve the symptoms of children,improve the body immunity,promote children rehabilitation,has good treatment effect.
RESUMO
Objective To investigate the efficacy and safety of sustained release metoprolol succinate (short for metoprolol) for patients with chronic heart failure. Methods 71 stable patients with chronic heart failure were randomly divided into metoprolol group (n=36) and placebo (n=35), once daily metoprolol ( initial daily dose, 11.875mg, double every 2 weeks, target dose 95mg once daily) was given to metoprolol group. The heart rate, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDd) and 6-min walking distance were observed. Results 2 months after the initiation of metoprolol treatment, dyspnea improved, heart rate reduced significantly(P< 0.05); 4 months after treatment, left ventricular ejection fraction and 6-min walking distance improved significantly (P<0.05 and P< 0.01) after 6 months; 6 months after treatment, left ventricular end diastolic diameter reduced significantly (P<0.05). In placebo group, heart rare reduced significantly (P<0.05) 4 months after treatment, 6 months after treatment, left ventricular ejection fraction and 6-min walking distance improved significantly (P<0.05), left ventricular end diastolic diameter reduced, but it was not significant (P0.05). Compared with placebo, composite end points (rehospitalization, cardiovascular mortality and total mortality) in metoproiol group reduced significantly (P<0.05). Conclusion Sustained release metoprolol succinate is effective mad safe for patients with chronic heart failure.